Augusto Pichard, MD, is Director of the Cardiac Catheterization Laboratory at MedStar Washington Hospital Center. In this capacity, he directs the performance of 5,600 angioplasties and 12,000 diagnostic catheterizations annually. Additionally, he is Vice Chair of the Board of the MedStar Heart Institute and a Professor of Medicine (Cardiology) at Georgetown University.
Dr. Pichard is active in clinical and basic research. His research expertise is in Invasive Cardiology, including percutaneous valve repair and replacement. In addition, he trains cardiologists in the percutaneous treatment of structural heart disease.
Dr. Pichard is board certified in Internal Medicine, Cardiovascular Disease, and Interventional Cardiology. He has written more than 500 manuscripts for peer-reviewed journals on numerous topics in Invasive Cardiology, including innovative heart disease treatment techniques. He also is active in national and international educational activities related to his specialty. Dr. Pichard serves on several editorial boards and is a fellow of numerous professional organizations, both in the United States and in Chile. He is a Charter Fellow of the Society for Cardiac Angiography.
His medical degree is from the Catholic University of Chile. He completed a residency in Internal Medicine at the Catholic University Hospital, Chile, and a fellowship in Cardiology at the Cleveland Clinic in Ohio.
Dr. Pichard's research interests include
- Invasive cardiology
- Structural heart disease
- Percutaneous valve repair and replacement
- Innovative treatment techniques
Safety and efficacy of the XIENCE V everolimus-eluting stent compared with first-generation drug-eluting stents in contemporary clinical practice
In this study, published in the American Journal of Cardiology (2012;109:1288-94), Dr. Pichard and colleagues assessed the long-term safety and efficacy of the new XIENCE V everolimus-eluting stent compared with first-generation stents. This retrospective analysis included 6,069 patients treated with CYPHER, TAXUS, and XIENCE stents. The new stent was associated with improved safety and reduction in all-cause mortality and stent thrombosis compared with older drug-eluting stents. The new stent, however, did not offer improvements in overall major adverse cardiovascular events, Q-wave myocardial infarction, or revascularization rates.
Incidence and predictors of acute kidney injury after transcatheter aortic valve replacement
Patients undergoing transcatheter aortic valve replacement (TAVR) are at increased risk for acute kidney injury (AKI). In this study, published in the American Heart Journal (2012;163:1031-6), Dr. Pichard and colleagues assessed the predictors and prognostic impact of AKI after TAVR and compared various criteria for AKI. Because even a small increase in baseline creatinine following TAVR is associated with worse outcomes, care in patient selection and management is needed.
- Research Areas